Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade
This article was originally published in The Pink Sheet Daily
Policy changes since FDA's first biosimilar approval produce a label that is more clearly different than, but also more closely tied to, its brand reference.
You may also be interested in...
Agency has scheduled only two advisory committee meetings in 2017; does it indicate the agency plans to conduct fewer meetings going forward?
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.